Developing the MyCancerGene Digital Health Portal to Improve Patients’ Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study
JMIR Formative Research · 2025
DOI: 10.2196/56282 ↗At a glance
Journal article in JMIR Formative Research, 2025. Written by Phillip Trieu and 18 co-authors. Institution: Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, United States. Major MEDLINE topics: Genetic Testing, Patient Portals, Neoplasms. Cited 1 times so far (Crossref); 72 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS.
Topics: Digitalisierung in der Pflege
Abstract (original language)
Background
The use of multigene panels has significantly increased the likelihood that genetic testing will leave patients with uncertainties regarding test interpretation, implications, and recommendations, which will change over time. Effective longitudinal care models are needed to provide patients with updated information and to obtain patient and family history updates.
Objective
To bridge this gap, we aimed to develop a patient- and genetic provider–informed digital genetic health portal (GHP), MyCancerGene, to improve longitudinal patient understanding of and responses to genetic testing.
Methods
We used a 5-step process to develop MyCancerGene. To better understand their interest in and willingness to use a digital GHP, we surveyed 307 patients who completed genetic testing (step 1). We completed qualitative interviews with 10 patients and a focus group with 17 genetic providers to inform the content and function of MyCancerGene (step 2). Next, we developed initial intervention content (step 3) and completed user testing of intervention content with 25 providers and 28 patients (step 4). After developing the prototype intervention, we completed usability testing with 8 patients for their feedback on the final content, functions, and ease of use (step 5).
Results
In surveys conducted in step 1, 90% of patients with positive results reported interest in a digital GHP, and over 75% of participants with variants of uncertain significance or uninformative negative results reported similar interest. The most frequently reported advantages among patients were increasing accessibility, convenience, and efficiency (103/224, 46%); keeping genetic information organized (54/224, 24.1%); and increasing or maintaining patient understanding of the information (38/224, 17%). In qualitative interviews (step 2), both patients and genetic providers endorsed the benefit of the tool for updating personal and family history and for providers to share new risk information, test interpretation, or other medical changes. Patient and provider input informed eight key components of the tool: (1) Landing Page, (2) Summary of Care page, (3) My Genetic Test Results page, (4) My Family History page, (5) Provide an Update page, (6) Review an Update page, (7) Resources page, and (8) the Screenings Tracker. They also recommended key functions, including the ability to download and print materials and the inclusion of reminders and engagement functions. Potential challenges identified by patients included privacy and security concerns (67/206, 32.5%) and the potential for electronic information to generate distress (20/206, 9.7%). While patients were comfortable with updates (ie, even variant reclassification upgrades or clinically significant results), 44% (11/25) of genetic providers were uncomfortable sharing variant reclassification upgrades through MyCancerGene.
Conclusions
MyCancerGene, a patient-centered digital GHP, was developed with extensive patient and genetic provider feedback and designed to enhance longitudinal patient understanding of and affective and behavioral responses to genetic testing, particularly in the era of evolving evidence and risk information.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, United States.
- Fox Chase Cancer Center, Temple University, Philadelphia, PA, United States.
- Grillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States.
- Thomas Jefferson University, Philadelphia, PA, United States.
- University of Pennsylvania, Philadelphia, PA, United States.
ORCID profiles: Phillip Trieu, Dominique Fetzer, Briana McLeod, Kathryn Schweickert, Lauren Gutstein, Brian Egleston, Susan Domchek, Linda Fleisher, Lynne Wagner, Kuang-Yi Wen, Cara Cacioppo, Jessica E Ebrahimzadeh, Dana Falcone, Claire Langer, Elisabeth Wood, Kelsey Karpink, Shelby Posen, Enida Selmani, Angela R Bradbury
Funding
- NCI NIH HHS
Cite
APA
Trieu, P., Fetzer, D., McLeod, B., Schweickert, K., Gutstein, L., Egleston, B., Domchek, S., Fleisher, L., Wagner, L., Wen, K. Y., Cacioppo, C., Ebrahimzadeh, J. E., Falcone, D., Langer, C., Wood, E., Karpink, K., Posen, S., Selmani, E., & Bradbury, A. R. (2025). Developing the MyCancerGene Digital Health Portal to Improve Patients’ Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study. JMIR Formative Research. https://doi.org/10.2196/56282
Vancouver
Trieu P, Fetzer D, McLeod B, Schweickert K, Gutstein L, Egleston B, et al. Developing the MyCancerGene Digital Health Portal to Improve Patients’ Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study. JMIR Formative Research. 2025. doi:10.2196/56282
BibTeX
@article{Trieu2025,
author = {Trieu, Phillip and Fetzer, Dominique and McLeod, Briana and Schweickert, Kathryn and Gutstein, Lauren and Egleston, Brian and Domchek, Susan and Fleisher, Linda and Wagner, Lynne and Wen, Kuang-Yi and Cacioppo, Cara and Ebrahimzadeh, Jessica E and Falcone, Dana and Langer, Claire and Wood, Elisabeth and Karpink, Kelsey and Posen, Shelby and Selmani, Enida and Bradbury, Angela R},
title = {Developing the MyCancerGene Digital Health Portal to Improve Patients’ Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study},
journal = {JMIR Formative Research},
year = {2025},
doi = {10.2196/56282}
}
EUVIMED